(NASDAQ: IMNN) Imunon's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.91%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.66%.
Imunon's earnings in 2026 is -$14,495,028.On average, 7 Wall Street analysts forecast IMNN's earnings for 2026 to be -$13,784,593, with the lowest IMNN earnings forecast at -$18,051,383, and the highest IMNN earnings forecast at -$9,679,420. On average, 6 Wall Street analysts forecast IMNN's earnings for 2027 to be -$11,499,583, with the lowest IMNN earnings forecast at -$18,553,105, and the highest IMNN earnings forecast at -$7,208,079.
In 2028, IMNN is forecast to generate -$7,812,185 in earnings, with the lowest earnings forecast at -$8,524,166 and the highest earnings forecast at -$7,414,024.